-
1
-
-
3142741275
-
Epidemiology of mesothelioma
-
Robinson B., and Chahinian A. (Eds), Martin Dunitz, London
-
De Kleck N., and Musk A. Epidemiology of mesothelioma. In: Robinson B., and Chahinian A. (Eds). Mesothelioma (2002), Martin Dunitz, London 339-350
-
(2002)
Mesothelioma
, pp. 339-350
-
-
De Kleck, N.1
Musk, A.2
-
2
-
-
33750182984
-
Malignant pleural mesothelioma: a comprehensive review
-
Ismail-Khan R., Robinson L., Williams C., Garrett C., Bepler G., and Simon G. Malignant pleural mesothelioma: a comprehensive review. Cancer Control 13 (2006) 255-263
-
(2006)
Cancer Control
, vol.13
, pp. 255-263
-
-
Ismail-Khan, R.1
Robinson, L.2
Williams, C.3
Garrett, C.4
Bepler, G.5
Simon, G.6
-
3
-
-
0031961891
-
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience
-
Curran D., Sahmoud T., Therasse P., et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16 (1998) 145-152
-
(1998)
J Clin Oncol
, vol.16
, pp. 145-152
-
-
Curran, D.1
Sahmoud, T.2
Therasse, P.3
-
4
-
-
1642576134
-
Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies
-
Coppola D., Szabo M., Boulware D., et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10 (2004) 184-190
-
(2004)
Clin Cancer Res
, vol.10
, pp. 184-190
-
-
Coppola, D.1
Szabo, M.2
Boulware, D.3
-
5
-
-
33646587019
-
Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma
-
Scherpereel A., Grigoriu B., Conti M., et al. Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 175 (2006) 1155-1160
-
(2006)
Am J Respir Crit Care Med
, vol.175
, pp. 1155-1160
-
-
Scherpereel, A.1
Grigoriu, B.2
Conti, M.3
-
6
-
-
26444506232
-
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels
-
Pass H., Lott D., Lonardo F., et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353 (2005) 1564-1573
-
(2005)
N Engl J Med
, vol.353
, pp. 1564-1573
-
-
Pass, H.1
Lott, D.2
Lonardo, F.3
-
7
-
-
0017255624
-
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients
-
Butchart E., Ashcroft T., Barnsley W., et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 31 (1976) 15-24
-
(1976)
Thorax
, vol.31
, pp. 15-24
-
-
Butchart, E.1
Ashcroft, T.2
Barnsley, W.3
-
8
-
-
0010061755
-
Natural history and clinical staging of malignant mesothelioma
-
Mattson K. Natural history and clinical staging of malignant mesothelioma. Eur J Respir Dis 63 Suppl 124 (1982) 87
-
(1982)
Eur J Respir Dis
, vol.63
, Issue.SUPPL. 124
, pp. 87
-
-
Mattson, K.1
-
9
-
-
0010064556
-
Therapeutic modalities in malignant pleural mesothelioma
-
Chretien J., and Hirsch A. (Eds), Masson, New York
-
Chahinian A. Therapeutic modalities in malignant pleural mesothelioma. In: Chretien J., and Hirsch A. (Eds). Disease of the pleura (1983), Masson, New York 224
-
(1983)
Disease of the pleura
, pp. 224
-
-
Chahinian, A.1
-
10
-
-
0004076384
-
-
Springer-Verlag, Berlin, New York 2nd revision.
-
Spiessl B., Beahrs O., Hermanek P., et al. International Union against Cancer. TNM Atlas: Illustrated Guide to the TNM/PTNM Classification of Malignant Tumours. 3rd ed. (1992), Springer-Verlag, Berlin, New York 2nd revision.
-
(1992)
International Union against Cancer. TNM Atlas: Illustrated Guide to the TNM/PTNM Classification of Malignant Tumours. 3rd ed.
-
-
Spiessl, B.1
Beahrs, O.2
Hermanek, P.3
-
11
-
-
0027211732
-
Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging
-
Boutin C., Rey F., Gouvernet J., et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 72 (1993) 394-404
-
(1993)
Cancer
, vol.72
, pp. 394-404
-
-
Boutin, C.1
Rey, F.2
Gouvernet, J.3
-
12
-
-
0027285687
-
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma
-
Sugarbaker D., Strauss G., Lynch T., et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11 (1993) 1172-1178
-
(1993)
J Clin Oncol
, vol.11
, pp. 1172-1178
-
-
Sugarbaker, D.1
Strauss, G.2
Lynch, T.3
-
13
-
-
0028825114
-
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group
-
Rusch V. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108 (1995) 1122-1128
-
(1995)
Chest
, vol.108
, pp. 1122-1128
-
-
Rusch, V.1
-
14
-
-
0031887839
-
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B
-
Herndon J., Green M., Chahinian A., et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113 (1998) 723-731
-
(1998)
Chest
, vol.113
, pp. 723-731
-
-
Herndon, J.1
Green, M.2
Chahinian, A.3
-
15
-
-
0033849171
-
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
-
Edwards J., Abrams K., Leverment J., et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55 (2000) 731-735
-
(2000)
Thorax
, vol.55
, pp. 731-735
-
-
Edwards, J.1
Abrams, K.2
Leverment, J.3
-
16
-
-
33746875641
-
A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer
-
Potti A., Mukherjee S., Petersen R., et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355 (2006) 570-580
-
(2006)
N Engl J Med
, vol.355
, pp. 570-580
-
-
Potti, A.1
Mukherjee, S.2
Petersen, R.3
-
18
-
-
0029928641
-
Chemotherapy in malignant pleural mesothelioma. A review
-
Ong S., and Vogelzang N. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 14 (1996) 1007-1017
-
(1996)
J Clin Oncol
, vol.14
, pp. 1007-1017
-
-
Ong, S.1
Vogelzang, N.2
-
19
-
-
0023840760
-
Malignant pleural mesothelioma: a disease unaffected by current therapeutic manoeuvres
-
Albert A., Falkson G., Goedhals L., et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic manoeuvres. J Clin Oncol 6 (1998) 527-535
-
(1998)
J Clin Oncol
, vol.6
, pp. 527-535
-
-
Albert, A.1
Falkson, G.2
Goedhals, L.3
-
20
-
-
0036837690
-
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with metaanalysis
-
Berghmans T., Paesmans M., Lalami Y., et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with metaanalysis. Lung Cancer 38 (2002) 111-121
-
(2002)
Lung Cancer
, vol.38
, pp. 111-121
-
-
Berghmans, T.1
Paesmans, M.2
Lalami, Y.3
-
21
-
-
0041629528
-
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
-
Vogelzang N., Rusthoven J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
-
(2003)
J Clin Oncol
, vol.21
, pp. 2636-2644
-
-
Vogelzang, N.1
Rusthoven, J.2
Symanowski, J.3
-
22
-
-
27744476091
-
Standard therapy for the treatment of malignant pleural mesothelioma
-
Vogelzang N. Standard therapy for the treatment of malignant pleural mesothelioma. Lung Cancer 50 Suppl 1 (2005) S23-S24
-
(2005)
Lung Cancer
, vol.50
, Issue.SUPPL. 1
-
-
Vogelzang, N.1
-
23
-
-
27244447448
-
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
-
van Meerbeeck J., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 (2005) 6881-6889
-
(2005)
J Clin Oncol
, vol.23
, pp. 6881-6889
-
-
van Meerbeeck, J.1
Gaafar, R.2
Manegold, C.3
-
24
-
-
33645449947
-
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
-
Ceresoli G., Zucali P., Favaretto A., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24 (2006) 1443-1448
-
(2006)
J Clin Oncol
, vol.24
, pp. 1443-1448
-
-
Ceresoli, G.1
Zucali, P.2
Favaretto, A.3
-
25
-
-
31544441696
-
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial
-
O'Brien M., Watkins D., Ryan C., et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 17 (2006) 270-275
-
(2006)
Ann Oncol
, vol.17
, pp. 270-275
-
-
O'Brien, M.1
Watkins, D.2
Ryan, C.3
-
26
-
-
34547549701
-
A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (PTS) with advanced malignant pleural mesothelioma (MPM)
-
Jassem J., Ramlau R., Santoro A., et al. A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (PTS) with advanced malignant pleural mesothelioma (MPM). Ann Oncol Suppl 9 (2006) ix214
-
(2006)
Ann Oncol
, Issue.SUPPL. 9
-
-
Jassem, J.1
Ramlau, R.2
Santoro, A.3
-
27
-
-
0026608650
-
Correlation of basic fibroblast growth factor expression levels with degree of malignancy and vascularity in human gliomas
-
Takahashi J., Fukumoto M., Igarashi K., et al. Correlation of basic fibroblast growth factor expression levels with degree of malignancy and vascularity in human gliomas. J Neurosurg 76 (1992) 792-798
-
(1992)
J Neurosurg
, vol.76
, pp. 792-798
-
-
Takahashi, J.1
Fukumoto, M.2
Igarashi, K.3
-
28
-
-
0025201337
-
Immunohistochemical localization of basic fibroblast growth factor in astrocytomas
-
Zagzag D., Miller D., Sato Y., et al. Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 50 (1990) 7393-7398
-
(1990)
Cancer Res
, vol.50
, pp. 7393-7398
-
-
Zagzag, D.1
Miller, D.2
Sato, Y.3
|